Compare PLG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | CRBU |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | PLG | CRBU |
|---|---|---|
| Price | $2.79 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 4.5M | 1.0M |
| Earning Date | 01-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $0.66 |
| 52 Week High | $3.36 | $3.54 |
| Indicator | PLG | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 40.12 |
| Support Level | $2.44 | $1.52 |
| Resistance Level | $2.66 | $1.80 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 85.93 | 25.00 |
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.